CIPLA : USFDA INSPECTION AT INVAGEN FACILITY ENDS WITH ZERO FORM 483 OBSERVATIONS

• USFDA conducted a routine cGMP inspection at InvaGen Pharmaceuticals Inc.'s manufacturing facility in Hauppauge, Long Island, New York, USA • Inspection was carried out from 19th October 2026 to 22nd October 2026 • The inspection concluded with zero Form 483 observations • InvaGen Pharmaceuticals Inc. is a wholly owned subsidiary of Cipla

Cipla Ltd

Open attachment

← Back to feed